Grant will advance UCLA research on lung cancer treatment

The treatment combines an immunotherapy agent called CCL21 with a drug delivery nanotechnology using biological particles called vaults. It was developed by Dr. Leonard Rome, associate director of UCLA’s California NanoSystems Institute, and Dr. Steven Dubinett, director of the UCLA Clinical Translational Science Institute, both of whom are also members of UCLA’s Jonsson Comprehensive Cancer Center.

Click here to read the full article in UCLA newsroom


Share via
Copy link
Powered by Social Snap